Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

Core Insights - Recursion has established a strong leadership position in the drug discovery space by leveraging AI/ML solutions and enhancing its technological and operational capabilities over the past decade [1][11] - The company is set to provide updated pipeline guidance during its Download Day event on June 24, 2024, aimed at investors and stakeholders [13] Pipeline Updates - Seven clinical trial readouts are anticipated within approximately 18 months, including: - REC-994 for Cerebral Cavernous Malformation with topline Phase 2 data readout in September 2024 - REC-2282 for Neurofibromatosis Type 2 with preliminary Phase 2 data readout in Q4 2024 - REC-4881 for Familial Adenomatous Polyposis with preliminary Phase 2 data readout in H1 2025 - REC-3964 for Clostridioides difficile Infection with Phase 2 study initiation in Q4 2024 and preliminary data readout by the end of 2025 [8] Partnership Developments - Recursion has delivered multiple data packages to Bayer and initiated its first joint oncology project, which is expected to advance rapidly towards Lead Series nomination [7][15] - Bayer will be the first external beta-user of Recursion's LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development, enhancing the research environment for both companies [7][15] Technological Advancements - The company has achieved significant milestones in its platform, including: - Potential to achieve an estimated 90 times the lab throughput compared to manual approaches [4] - Development of a genome-scale transcriptomics knockout map and multimodal mapping, which has shown a 90% success rate in predicting compounds that failed later disease-relevant assays [4][11] Company Overview - Recursion is a leading clinical stage TechBio company focused on decoding biology to industrialize drug discovery, utilizing a platform that integrates diverse technologies and one of the world's largest proprietary biological, chemical, and patient-centric datasets [11][14]